← Back to headlines
Madrigal Pharmaceuticals Projects 2026 Gross-to-Net, Advances F4c Outcomes
Madrigal Pharmaceuticals anticipates its 2026 gross-to-net revenue to be in the mid-to-high 30s, while also progressing towards an F4c outcomes readout expected in 2027.
6 May, 18:02 — 6 May, 18:02
Sources
Showing 1 of 1 sources
Related Stories
Hantavirus Case on MV Hondius Cruise Ship Prompts Global Response
14m ago
Hantavirus Alarm Prompts Pandemic Concerns, COVID-Style Responses
14m ago
Hantavirus Outbreak Ship MV Hondius Handled in Canary Islands
25m ago
Fear and weariness in the Canary port over hantavirus: 'They always bring to the Canaries what nobody wants'
25m ago